- AU$6.98m
- AU$8.23m
- AU$4.53m
Brief: Acrux Receives FDA Approval For Generic Version Of Aczone® Gel, 5% (Dapsone Gel 5%)
Acrux eyes best day in over 4 months on intellectual property deal
Brief: Acrux Announces Gedeon Richter Buyout Of Future Lenzetto Royalties For Eur4.1 Million
Brief: Acrux Says It Got Positive FDA Remote Regulatory Assessment
Brief: Acrux Says Co And Amring Pharmaceuticals Mutually Agreed To Terminate Agreement
Brief: Acrux Sees Regulatory Approval For Two Of Topical Generic Products This Year
Brief: Acrux Ltd Posts FY Net Loss Attributable A$9.8 Million
Brief: Acrux Says Its Sixth Generic Application Accepted By U.S. FDA For Review
Australia's Acrux rises on deal with U.S.-based Padagis
Brief: Acrux Has Entered Into An Exclusive Commercialisation Agreement With Padagis
Australia Stock Exchange release from ACRUX : Appendix 3Y - Brumley
Australia Stock Exchange release from ACRUX : Application for quotation of securities - ACR
Australia Stock Exchange release from ACRUX : Appendix 3Y - Ross Dobinson
Australia Stock Exchange release from ACRUX : Updated Continuous Disclosure & Shareholder Reporting Policy
Australia Stock Exchange release from ACRUX : Application for quotation of securities - ACR
Australia Stock Exchange release from ACRUX : Updated Board Charter
Brief: Acrux Ltd Says HY Total Comprehensive Loss Attributable A$5.5 Mln
Australia Stock Exchange release from ACRUX : Appendix 4D, Half Year Accounts as at 31 December 2021
Australia Stock Exchange release from ACRUX : PRE_NR Ends: 13:12:36